Use of oral anticoagulants in atrial fibrillation is highly variable and only weakly associated with estimated stroke risk: Cross-sectional population database study

European Journal of General Practice

Volumn 20, Issue 3, 2014, Pages 181-189

  Dreischulte, Tobias ^a,b   Barnett, Karen ^b   Madhok, Vishnu ^a   Guthrie, Bruce ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Antithrombotics; Atrial fibrillation; Family practice; Quality of health care; Stroke risk

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; ANTICOAGULANT AGENT;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DEMENTIA; DRUG USE; FEMALE; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PEPTIC ULCER; PRIMARY MEDICAL CARE; RHEUMATIC HEART DISEASE; ATRIAL FIBRILLATION; COMPLICATION; DECISION MAKING; FACTUAL DATABASE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SCOTLAND; STANDARDS; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DECISION MAKING; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; SCOTLAND; STROKE;

EID: 84907350219     PISSN: 13814788     EISSN: 17511402     Source Type: Journal    
DOI: 10.3109/13814788.2013.852535     Document Type: Article

References (43)

1. Stewart S HC, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21.
2. Miyasaka YM, Barnes BJ, Gersh, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-25.
3. Go AS HE, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) Study. J Am Med Assoc. 2001; 285: 2370-5.
4. Camm A J, Kirchhof P, Lip G YH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. Europace 2010; 12: 1360-420.
5. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FDR, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation. Stroke 2009; 40: 1410-6.
6. Hart R G, Pearce L A, Aguilar M I. M eta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-67.
7. Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000; 355: 956-62.
8. Jowett S, Bryan S, Mant J, Fletcher K, Roalfe A, Fitzmaurice D, et al. Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. Stroke 2011; 42: 1717-21.
9. Ogilvie I M, Welner S A, Cowell W, Lip G Y. I schaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. J Thromb Haemost. 2011; 106: 34-44.
10. National Institute for Health and Clinical Excellence. A trial fibrillation: National clinical guideline for management in primary and secondary care. London: NICE; 2006.
11. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008; 133 (6 Suppl): 546-92.
12. Ogilvie IM, Newton N, Welner S. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010: 638-45.
13. Holt T A, Hunter T D, Gunnarsson C, Khan N, Cload P, Lip G YH. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Brit J Gen Pract. 2012; 62: 710-17.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. J Am Med Assoc. 2001; 285: 2864-70.
15. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. American College of Cardiology Foundation/ American Heart Association Task Force on guidelines for the management of patients with atrial fibrillation: A report of the 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ ESC 2006 practice guidelines. Circulation 2011; 123: e269-e367.
16. Borman NL, Kalra PA, Kalra PR. Acute kidney injury in patients with decompensated heart failure. Brit J Hosp Med. 2010; 71: 269-75.
17. British Medical Association and NHS Employers. Quality and outcomes framework for 2012/13. Guidance for PCOs and practices (p118). Available at http://www.nhsemployers.org/ Aboutus/Publications/Documents/QOF-2012-13.pdf (accessed 12 November 2013).
18. Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score 1. J Thromb Haemost. 2010; 103: 833-40.
19. Lip GYH. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score 1]: Simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. J Thromb Haemost. 2010; 103: 683-5.
20. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation - friend or foe? J Thromb Haemost. 2010; 104: 45-8.
21. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation. Chest 2008; 133: 546S-92S.
22. Van Staa T P, Setakis E, D i Tanna G L, Lane D A, Lip G YH. A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011; 9: 39-48.
23. Elder R, Kirkpatrick M, Ramsay W, MacLeod M, Guthrie B, Sutton M, et al. Measuring quality in primary medical services using data from SPICE. Edinburgh: Information and Statistics Division, NHS National Services Scotland; 2007.
24. NHS England: Primary Care Commissioning. Q OF implementation: Business rules. Available at http://www.pcc.nhs.uk/145 (accessed 12 November 2013).
25. Carstairs V, Morris R. Deprivation and health in Scotland. Aberdeen: Aberdeen University Press; 1991.
26. Guthrie B, Clark SA, McCowan C. The burden of psychotropic drug prescribing in people with dementia: A population database study. Age Ageing 2010; 39: 637-42.
27. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: Cross sectional population database analysis in Scottish general practice. Br Med J. 2011; 342: d3514.
28. Dreischulte T, Grant A, McCowan C, McAnaw J, Guthrie B. Quality and safety of medication use in primary care: Consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement. Br Med C Clin Pharmacol. 2012; 12: 5.
29. Larsen K, Merlo J. Appropriate assessment of neighbourhood effects on individual health: Integrating random and fixed effects in multilevel logistic regression. Am J Epidemiol. 2007; 161: 81-8.
30. Lip G, Huber K, Andreotti F, Arnesen H, Airaksinen J, Cuisset T, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary - a consensus document of the European Society of Cardiology working group on thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010; 31: 1311-8.
31. Hansen ML, Sorensen R, Mette T, Fog-Petersen M, Rauns øJ, Gadsbøll N, et al. Less is more. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 16: 170-5.
32. Lip G YH, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, et al. Bleeding risk assessment and management in atrial fibrillation patients: A position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011; 13: 723-46.
33. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: A systematic review. Age Ageing 2011; 40: 675-83.
34. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, et al. Antithrombotic treatment in real-life atrial fibrillation patients: A report from the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2006; 27: 3018-26.
35. Gallagher AM RS, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: Do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008; 6: 1500-6.
36. NHS improvement. Guidance on risk assessment and stroke prevention for atrial fibrillation (GRASP-AF). Available at http://www. improvement.nhs.uk/ graspaf/ (accessed 27 February 2013).
37. Mant J, Hobbs FR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493- 503.
38. National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE Technology appraisal guidance 256. Available at http://www.nice.org.uk/nicemedia/live/13746/ 59295/59295.pdf (accessed 12 November 2013).
39. Scottish Medicines Consortium (SMC) No. (852/13). R ivaroxaban 15 and 20 mg film-coated tablets. Available at http://www.scottishmedicines. org.uk/files/advice/rivaroxaban-Xarelto-for-AF- FINAL-Jan-2012-for-website.pdf (accessed 12 November 2013).
40. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-100.
41. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage - results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151: 713-9.
42. Hohnloser SH. Stroke prevention versus bleeding risk in atrial fibrillation - a clinical dilemma. J Am Coll Cardiol. 2011; 57: 181-3.
43. Pamukcu B, Lip GYH, Lane DA. Simplifying stroke risk stratification in atrial fibrillation patients: Implications of the CHA2DS2-VASc risk stratification scores. Age Ageing 2010: afq059.